{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T07:27:05Z","timestamp":1788852425886,"version":"build-2803163510"},"reference-count":41,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T00:00:00Z","timestamp":1669248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI","award":["JP18K09018"],"award-info":[{"award-number":["JP18K09018"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Tumor-induced osteomalacia (TIO) is one of the most common forms of acquired fibroblast growth factor 23 (FGF23)-related hypophosphatemia and is usually caused by phosphaturic mesenchymal tumors (PMTs). Although the complete resection of PMTs can cure TIO, preoperative localization of tumors by standard imaging modalities is often challenging. In addition to 18F-fluoro-2-deoxy-D-glucose positron emission tomography\u2013computed tomography (FDG-PET) and 111In-pentetreotide scintigraphy (SRS), systemic FGF23 venous sampling (FGF23VS) has been used to help localize PMTs in specialized institutions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>This study aimed to evaluate the diagnostic performance of each imaging test and their combinations in localizing PMTs.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In an observational retrospective study of patients with adult-onset FGF23-related osteomalacia who underwent all 3 imaging studies (FDG-PET, SRS, and FGF23VS), the rate of successful preoperative localization of the tumors was evaluated only in the patients with pathological diagnoses of PMTs, considering the possibility that pathogenesis of patients without identified tumors might be due to other causes such as late-onset hereditary FGF23-related hypophosphatemia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 30 Japanese patients with TIO (median age, 60 years [range, 28-87 years]; 10 women [33.3%]) were included in the study. The success rate of preoperative localization for each test and combinations of 2 or 3 tests among 18 patients with PMTs was as follows: 72% (FDG-PET), 72% (SRS), 94% (FGF23VS), 89% (FDG-PET, SRS), 100% (FDG-PET, FGF23VS), 94% (SRS, FGF23VS), and 100% (FDG-PET, SRS, and FGF23VS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>We observed the highest localization rate of PMTs in patients with identified PMTs with the combination of FDG-PET and FGF23VS.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jendso\/bvac181","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T01:41:46Z","timestamp":1669340506000},"source":"Crossref","is-referenced-by-count":15,"title":["Utility of Multimodality Approach Including Systemic FGF23 Venous Sampling in Localizing Phosphaturic Mesenchymal Tumors"],"prefix":"10.1210","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9178-7846","authenticated-orcid":false,"given":"Hajime","family":"Kato","sequence":"first","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"},{"name":"Osteoporosis Center, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minae","family":"Koga","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"},{"name":"Osteoporosis Center, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6583-0879","authenticated-orcid":false,"given":"Yuka","family":"Kinoshita","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"},{"name":"Osteoporosis Center, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5450-2247","authenticated-orcid":false,"given":"Naoko","family":"Hidaka","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"},{"name":"Osteoporosis Center, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5226-2227","authenticated-orcid":false,"given":"Yoshitomo","family":"Hoshino","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"},{"name":"Osteoporosis Center, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3728-1139","authenticated-orcid":false,"given":"Yuichi","family":"Takashi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Diabetes Mellitus, Fukuoka University School of Medicine , Fukuoka, 814-0180 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Arai","sequence":"additional","affiliation":[{"name":"Division of Molecular Physiology and Metabolism, Faculty of Medicine, Tohoku University , Miyagi, 980-8575 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Katsura","sequence":"additional","affiliation":[{"name":"Department of Radiology, Graduate School of Medicine, The University of Tokyo , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-8048","authenticated-orcid":false,"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine Kyoto University , Kyoto, 606-8507 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6991-747X","authenticated-orcid":false,"given":"Naohiro","family":"Makise","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Medicine, The University of Tokyo , Tokyo, 113-8655 , Japan"},{"name":"Division of Surgical Pathology, Chiba Cancer Center , Chiba, 260-8717 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Ushiku","sequence":"additional","affiliation":[{"name":"Department of Pathology, Graduate School of Medicine, The University of Tokyo , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of Oral-maxillofacial Surgery, Dentistry and Orthodontics, and Division of Tissue Engineering, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7401-2934","authenticated-orcid":false,"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5722-115X","authenticated-orcid":false,"given":"Noriko","family":"Makita","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"},{"name":"Osteoporosis Center, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3610-3469","authenticated-orcid":false,"given":"Seiji","family":"Fukumoto","sequence":"additional","affiliation":[{"name":"Fujii Memorial Institute of Medical Sciences, Institute of Advanced Medical Sciences, Tokushima University , Tokushima, 770-8503 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4071-5372","authenticated-orcid":false,"given":"Nobuaki","family":"Ito","sequence":"additional","affiliation":[{"name":"Division of Nephrology and Endocrinology, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"},{"name":"Osteoporosis Center, The University of Tokyo Hospital , Tokyo, 113-8655 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2022,11,24]]},"reference":[{"issue":"9","key":"2022122218205268400_bvac181-B1","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1507\/endocrj.EJ15-0275","article-title":"Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment","volume":"62","author":"Endo","year":"2015","journal-title":"Endocr J"},{"issue":"1","key":"2022122218205268400_bvac181-B2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"2022122218205268400_bvac181-B3","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00223-021-00843-2","article-title":"Epidemiology of tumor-induced osteomalacia in Denmark","volume":"109","author":"Abrahamsen","year":"2021","journal-title":"Calcif Tissue Int"},{"key":"2022122218205268400_bvac181-B4","doi-asserted-by":"crossref","first-page":"116064","DOI":"10.1016\/j.bone.2021.116064","article-title":"Challenges in the management of tumor-induced osteomalacia (TIO)","volume":"152","author":"Brandi","year":"2021","journal-title":"Bone"},{"issue":"10","key":"2022122218205268400_bvac181-B5","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1001\/jama.294.10.1260","article-title":"Tumor-induced osteomalacia","volume":"294","author":"Jan De Beur","year":"2005","journal-title":"JAMA"},{"issue":"7","key":"2022122218205268400_bvac181-B6","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1507\/endocrj.EJ16-0587","article-title":"The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases","volume":"64","author":"Feng","year":"2017","journal-title":"Endocr J"},{"issue":"17","key":"2022122218205268400_bvac181-B7","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1056\/NEJMoa020881","article-title":"Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia","volume":"348","author":"Jonsson","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"2022122218205268400_bvac181-B8","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00774-021-01258-7","article-title":"Performance evaluation of the new chemiluminescent intact FGF23 assay relative to the existing assay system","volume":"40","author":"Kato","year":"2022","journal-title":"J Bone Miner Metab"},{"issue":"6","key":"2022122218205268400_bvac181-B9","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1007\/s00774-021-01250-1","article-title":"Clinical performance of a novel chemiluminescent enzyme immunoassay for FGF23","volume":"39","author":"Ito","year":"2021","journal-title":"J Bone Miner Metab"},{"issue":"4","key":"2022122218205268400_bvac181-B10","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"issue":"2","key":"2022122218205268400_bvac181-B11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten","year":"2009","journal-title":"Ann Clin Biochem"},{"key":"2022122218205268400_bvac181-B12","doi-asserted-by":"crossref","first-page":"101144","DOI":"10.1016\/j.bonr.2021.101144","article-title":"Induction of FGF23-related hypophosphatemic osteomalacia by alcohol consumption","volume":"15","author":"Hidaka","year":"2021","journal-title":"Bone Rep"},{"issue":"11","key":"2022122218205268400_bvac181-B13","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1007\/s11999-013-3178-1","article-title":"The phosphaturic mesenchymal tumor: why is definitive diagnosis and curative surgery often delayed?","volume":"471","author":"Ledford","year":"2013","journal-title":"Clin Orthop Relat Res"},{"issue":"5","key":"2022122218205268400_bvac181-B14","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1586\/eem.09.27","article-title":"Tumor-induced osteomalacia","volume":"4","author":"Farrow","year":"2009","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"2","key":"2022122218205268400_bvac181-B15","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jbmr.4184","article-title":"Interim analysis of a phase 2 open-label trial assessing burosumab efficacy and safety in patients with tumor-induced osteomalacia","volume":"36","author":"Imanishi","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2022122218205268400_bvac181-B16","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/jbmr.4233","article-title":"Burosumab for the treatment of tumor-induced osteomalacia","volume":"36","author":"de Beur","year":"2021","journal-title":"J Bone Miner Res"},{"issue":"8","key":"2022122218205268400_bvac181-B17","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1210\/jc.2004-0406","article-title":"Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia","volume":"89","author":"Takeuchi","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2022122218205268400_bvac181-B18","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1365-2796.2010.02262.x","article-title":"Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia","volume":"268","author":"Ito","year":"2010","journal-title":"J Intern Med"},{"issue":"2","key":"2022122218205268400_bvac181-B19","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/00003072-199902000-00016","article-title":"Indium-111 pentetreotide scintigraphy of mesenchymal tumor with oncogenic osteomalacia","volume":"24","author":"Nguyen","year":"1999","journal-title":"Clin Nucl Med"},{"issue":"26","key":"2022122218205268400_bvac181-B20","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa010839","article-title":"Octreotide therapy for tumor-induced osteomalacia","volume":"345","author":"Seufert","year":"2001","journal-title":"N Engl J Med"},{"issue":"9308","key":"2022122218205268400_bvac181-B21","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0140-6736(02)07846-7","article-title":"Localisation of mesenchymal tumours by somatostatin receptor imaging","volume":"359","author":"Beur","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"2022122218205268400_bvac181-B22","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1016\/j.humpath.2013.07.016","article-title":"Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A)","volume":"44","author":"Houang","year":"2013","journal-title":"Hum Pathol"},{"issue":"2","key":"2022122218205268400_bvac181-B23","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1210\/jc.2012-3642","article-title":"Improving diagnosis of tumor-induced osteomalacia with gallium-68 DOTATATE PET\/CT","volume":"98","author":"Clifton-Bligh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2022122218205268400_bvac181-B24","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1210\/jc.2016-2052","article-title":"68Ga-DOTATATE For tumor localization in tumor-induced osteomalacia","volume":"101","author":"El-Maouche","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2022122218205268400_bvac181-B25","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1007\/s00259-018-3971-x","article-title":"Diagnostic performance and impact on patient management of 68Ga-DOTA-TOC PET\/CT for detecting osteomalacia-associated tumours","volume":"45","author":"Paquet","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"2022122218205268400_bvac181-B26","first-page":"311","article-title":"Somatostatin receptor PET ligands\u2014the next generation for clinical practice","volume":"8","author":"Pauwels","year":"2018","journal-title":"Am J Nucl Med Mol Imaging"},{"issue":"3","key":"2022122218205268400_bvac181-B27","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.bone.2005.01.001","article-title":"Oncogenic osteomalacia: diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET\/CT SCAN for the diagnosis and follow-up in one case","volume":"36","author":"Dupond","year":"2005","journal-title":"Bone"},{"issue":"6","key":"2022122218205268400_bvac181-B28","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/jbmr.316","article-title":"Selective venous catheterization for the localization of phosphaturic mesenchymal tumors","volume":"26","author":"Andreopoulou","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2022122218205268400_bvac181-B29","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/jbmr.1881","article-title":"Tumor localization and biochemical response to cure in tumor-induced osteomalacia","volume":"28","author":"Chong","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2022122218205268400_bvac181-B30","doi-asserted-by":"crossref","first-page":"981","DOI":"10.3349\/ymj.2017.58.5.981","article-title":"Localization of oncogenic osteomalacia by systemic venous sampling of fibroblast growth factor 23","volume":"58","author":"Lee","year":"2017","journal-title":"Yonsei Med J"},{"issue":"8","key":"2022122218205268400_bvac181-B31","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/jbmr.4620","article-title":"Clinical challenges in diagnosis, tumor localization and treatment of tumor-induced osteomalacia: outcome of a retrospective surveillance","volume":"37","author":"Hidaka","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"7929","key":"2022122218205268400_bvac181-B32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(75)92736-1","article-title":"Nomogram for derivation of renal threshold phosphate concentration","volume":"306","author":"Walton","year":"1975","journal-title":"Lancet"},{"issue":"3","key":"2022122218205268400_bvac181-B33","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/jbmr.3903","article-title":"Nonremission and recurrent tumor-induced osteomalacia: a retrospective study","volume":"35","author":"Li","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"11","key":"2022122218205268400_bvac181-B34","doi-asserted-by":"crossref","first-page":"4957","DOI":"10.1210\/jc.2002-021105","article-title":"Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets\/osteomalacia","volume":"87","author":"Yamazaki","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"7616","key":"2022122218205268400_bvac181-B35","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nature19057","article-title":"Analysis of protein-coding genetic variation in 60,706 humans","volume":"536","author":"Lek","year":"2016","journal-title":"Nature"},{"issue":"9","key":"2022122218205268400_bvac181-B36","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2188\/jea.JE20150268","article-title":"The tohoku medical megabank project: design and mission","volume":"26","author":"Kuriyama","year":"2016","journal-title":"J Epidemiol"},{"key":"2022122218205268400_bvac181-B37","author":"Kato"},{"issue":"6","key":"2022122218205268400_bvac181-B38","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1002\/hed.25657","article-title":"Tumor-induced hypophosphatemic osteomalacia caused by a mesenchymal tumor of the mandible managed by a segmental mandibulectomy and microvascular reconstruction with a free fibula flap","volume":"41","author":"Acharya","year":"2019","journal-title":"Head Neck"},{"issue":"1","key":"2022122218205268400_bvac181-B39","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/cen.12426","article-title":"Functional imaging in primary tumour-induced osteomalacia: relative performance of FDG PET\/CT vs somatostatin receptor-based functional scans: a series of nine patients","volume":"81","author":"Jadhav","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"1","key":"2022122218205268400_bvac181-B40","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1097\/RLU.0000000000000460","article-title":"Comparison of 18F-FDG and 68Ga DOTATATE PET\/CT in localization of tumor causing oncogenic osteomalacia","volume":"40","author":"Agrawal","year":"2015","journal-title":"Clin Nucl Med"},{"issue":"3","key":"2022122218205268400_bvac181-B41","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s12149-021-01575-x","article-title":"Diagnostic performance of 68Ga-DOTATOC PET\/CT in tumor-induced osteomalacia","volume":"35","author":"Kato","year":"2021","journal-title":"Ann Nucl Med"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvac181\/47257838\/bvac181.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/2\/bvac181\/48027607\/bvac181.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/7\/2\/bvac181\/48027607\/bvac181.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T18:21:15Z","timestamp":1671733275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvac181\/6845657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,24]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,12,15]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvac181","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,11,24]]},"article-number":"bvac181"}}